Cardiology

ACC: Niacin/Laropiprant no benefit in vascular disease

(HealthDay)—For patients with preexisting occlusive vascular disease, the combination of niacin and the anti-flushing agent laropiprant provides no benefit and is associated with an increase in serious side effects, according ...

Other

Merck 3Q net income falls on charges, lower sales

Merck & Co. said Monday that its third-quarter profit plunged 35 percent because of competition from generic drugs, lower sales of its top-selling medicine, and restructuring and acquisition charges. It still beat Wall Street's ...

Medications

Merck says FDA reviewing its ragweed allergy therapy

Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...

Medications

Merck says cholesterol drug failed to show benefit

Drugmaker Merck & Co. said it will not seek U.S. approval for its cholesterol drug Tredaptive and is recommending doctors abroad stop prescribing it to new patients, based on failed study results.

Genetics

Genetic variant may explain weight loss post-RYGB surgery

(HealthDay)—A genetic variant associated with weight loss after Roux-en-Y gastric bypass (RYGB) surgery has been identified, according to a study published in the May 2 issue of the American Journal of Human Genetics.

page 7 from 14